The in vitro effect of antirheumatic drugs on platelet function

References

• Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130–136. doi:10.1016/j.autrev.2004.09.002. PMID: 15823498.
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690–1697. doi:10.1002/art.24092. PMID: 19035419.
   PubMed Web of Science ®Google Scholar
• Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015;11:693–704. doi:10.1038/nrrheum.2015.112. PMID: 26282082.
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011;31:153–164. doi:10.1007/s00296-010-1446-x. PMID: 20390282.
   PubMed Web of Science ®Google Scholar
• Puurunen MK, Hwang SJ, Larson MG, Vasan RS, O’Donnell CJ, Tofler G, Johnson AD. ADP platelet hyperreactivity predicts cardiovascular disease in the FHS (Framingham Heart Study). J Am Heart Assoc 2018;7:e008522. doi:10.1161/JAHA.118.008522. PMID: 29502103.
   PubMed Web of Science ®Google Scholar
• Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480–489. doi:10.1136/annrheumdis-2014-206624. PMID: 25561362.
   PubMed Web of Science ®Google Scholar
• Naranjo A, Sokka T, Descalzo M, Calvo-Alén J, Hørslev-Petersen K, Luukkainen R, Combe B, Burmester GR, Devlin J, Ferraccioli G, et al. Cardiovasclar disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30. doi:10.1186/ar2383. PMID: 18325087.
   PubMed Web of Science ®Google Scholar
• Sharma ST, Wasko MCM, Tang X, Vedamurthy D, Yan X, Cote J, Bili A. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc 2016;5:e002867. doi:10.1161/JAHA.115.002867. PMID: 26727968.
   PubMed Web of Science ®Google Scholar
• MacMullan PA, Madigan AM, Paul N, Peace AJ, Alagha A, Nolan KB, McCarthy GM, Kenny D. Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. Clin Rheumatol 2016;35:447–455. doi:10.1007/s10067-014-2769-x. PMID: 25253538.
   PubMed Web of Science ®Google Scholar
• Achuthan S, Ahluwalia J, Shafiq N, Bhalla A, Pareek A, Chandurkar N, Malhotra S. Hydroxychloroquine’s efficacy as an antiplatelet agent study in healthy volunteers: a proof of concept study. J Cardiovasc Pharmacol Ther 2015;20:174–180. doi:10.1177/1074248414546324. PMID: 25125385.
   PubMed Web of Science ®Google Scholar
• Städtler R, von Kries R, Göbel U. Platelet function and high-dose methotrexate treatment with citrovorum factor rescue. Onkologie 1984;7:238–242. doi:10.1159/000215448. PMID: 6384866.
   PubMedGoogle Scholar
• Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥ 15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 2014;73:1549–1551. doi:10.1136/annrheumdis-2014-205228. PMID: 24728329.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Waller RD, Stebbings S, Highton J, Orlovich DA, Schmierer D, Fawcett JP. The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study. Int J Rheum Dis 2010;13:48–54. doi:10.1111/j.1756-185X.2009.01449.x. PMID: 20374384.
   PubMed Web of Science ®Google Scholar
• Miller DR, Fiechtner JJ, Carpenter JR, Brown RR, Stroshane RM, Stecher VJ. Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 1987;30:567–571. PMID: 3593438.
   PubMed Web of Science ®Google Scholar
• Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41:421–430. doi:10.2165/00003088-200241060-00003. PMID: 12074690.
   PubMed Web of Science ®Google Scholar
• Taggert AJ, Astbury C, Dixon JS, Bird HA. Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma. Clin Rheumatol 1986;5:327–331. PMID: 3780140.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Lu P, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69–74. doi:10.1136/annrheumdis-2013-203523. PMID: 23904473.
   PubMed Web of Science ®Google Scholar
• Iwahashi M, Inoue H, Matsubara T, Tanaka T, Amano K, Kanamono T, Nakano T, Uchimura S, Izumihara T, Yamazaki A, et al. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. Mod Rheumatol 2014;24:885–891. doi:10.3109/14397595.2014.881954. PMID: 24708204.
   PubMed Web of Science ®Google Scholar
• Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119–1128. doi:10.1177/0091270007305297. PMID: 17766699.
   PubMed Web of Science ®Google Scholar
• St Clair EW, Wagner C, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451–1459. doi:10.1002/art.10302. PMID: 12115174.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Mivasaka N, Kawai S, Sugiyama N, Yuasa H, Yamashita N, Sugiyama N, Wagerle LC, Vlahos B, Wajdula J. Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials. Mod Rheumatol 2015;25:173–186. doi:10.3109/14397595.2014.914014. PMID: 24842477.
   PubMed Web of Science ®Google Scholar
• Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 2005;34:12–18. doi:10.1016/j.semarthrit.2005.01.004. PMID: 15852249.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Lyn S, Ly Y, Xu Z, Bouman-Thio E, Masterson T, Ford JA, Keen M, Petty KJ, Davis HM, et al. Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial. Clin Drug Investig 2013;33:795–800. doi:10.1007/s40261-013-0124-7. PMID: 23975656.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D’Haens G. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol Hepatol 2014;12:423–431. doi:10.1016/j.cgh.2013.10.025. PMID: 24184736.
   PubMed Web of Science ®Google Scholar
• Vinholt PJ, Nybo M, Nielsen CB, Hvas A-M. Light transmission aggregometry using pre-coated microtiter plates and a Victor X5 plate reader. PLoS ONE 2017;12:e0185675. doi:10.1371/journal.pone.0185675. PMID: 29023589.
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Lowe GC, Kirkby NS, Chan MV, Lundberg MH, Morgan NV, Bem D, Nisar SP, Leo VC, Jones ML, et al. Characterization of multiple platelet activation pathways in patients with bleeding as high-throughput screening option: use of 96-well Optimul assay. Blood 2014;123:11–22. doi:10.1182/blood-2013-08-520387. PMID: 24408324.
   PubMed Web of Science ®Google Scholar
• Vinholt PJ, Frederiksen H, Hvas A-M, Sprogøe U, Nielsen C. Measurement of platelet aggregation, independently of patient platelet count: a flow-cytometric approach. J Thromb Haemost 2017;15:1191–1202. doi:10.1111/jth.13675. PMID: 28296243.
   PubMed Web of Science ®Google Scholar
• Rubak P, Nissen PH, Kristensen SD, Hvas A-M. Investigation of platelet function and platelet disorders using flow cytometry. Platelets 2016;27:66–74. doi:10.3109/09537104.2015.1032919. PMID: 25901600.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Bonar R. External quality assessment/proficiency testing and internal quality control for the PFA-100 and PFA-200: an update. Semin Thromb Hemost 2014;40:239–253. doi:10.1055/s-0034-1365844. PMID: 24497116.
   PubMed Web of Science ®Google Scholar
• MacMullan PA, Peace AJ, Madigan AM, Tedesco AF, Kenny D, McCarthy GM. Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine disphosphate pathway: a novel finding and potential therapeutic target. Rheumatology (Oxford) 2010;49:240–245. doi:10.1093/rheumatology/kep377. PMID: 19965976.
   PubMed Web of Science ®Google Scholar
• Bisoendial RJ, Levi M, Tak PP, Stroes ES. The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular event. Semin Thromb Hemost 2010;36:452–457. doi:10.1055/s-0030-1254054. PMID: 20614397.
   PubMed Web of Science ®Google Scholar
• Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003;30:1182–1190. PMID: 12784387.
   PubMed Web of Science ®Google Scholar
• Thomason JM, Archer TM, Wills RW, Mackin AJ. Effects of immunosuppressive agents on hemostatic system in normal dogs. J Vet Intern Med 2018;32:1325–1333. doi:10.1111/jvim.15132. PMID: 29749651.
   PubMed Web of Science ®Google Scholar
• Liverani E, Banerjee S, Roberts W, Naseem KM, Perretti M. Prednisolone exerts exquisite inhibitory properties on platelet functions. Biochem Pharmacol 2012;83:1364–1373. doi:10.1016/j.bcp.2012.02.006. PMID: 22366284.
   PubMed Web of Science ®Google Scholar
• Moraes LA, Paul-Clark MJ, Rickman A, Flower RJ, Goulding NJ, Perretti M. Ligand-specific glucocorticoid receptor activation in human platelets. Blood 2005;106:4167–4175. doi:10.1182/blood-2005.04.1723. PMID: 16131566.
   PubMed Web of Science ®Google Scholar
• Cognasse F, Garraud O, Marotte H. Unlike tocilizumab, etanercept slightly increases experimental thrombin-induced aggregation in healthy individuals. Joint Bone Spine 2017;84:373–375. doi:10.1016/j.jbspin.2016.04.010. PMID: 27324601.
   PubMed Web of Science ®Google Scholar
• Manfredi AA, Baldini M, Camera M, Baldissera E, Brambilla M, Peretti G, Maseri A, Rovere-Querini P, Tremoli E, Sabbadini MG, et al. Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1511–1520. doi:10.1136/annrheumdis-2015-208442. PMID: 26819099.
   PubMed Web of Science ®Google Scholar
• Bunescu A, Seideman P, Lenkei R, Levin K, Egberg N. Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 2004;31:2347–2355. PMID: 15570633.
   PubMed Web of Science ®Google Scholar
• Paul M, Hemshekhar M, Thushara RM, Sundaram MS, NaveenKumar SK, Naveen S, Devaraja S, Somyajit K, West R, Basappa, et al. Methotrexate promotes platelet apoptosis via JNK-mediated mitochondrial damage: alleviation by N-acetylcysteine and N-acetylcysteine amid. PLoS One 2015;10:e0127558. doi:10.1371/journal.pone.0127558. PMID: 26083398.
   PubMed Web of Science ®Google Scholar
• Provan SA, Berg IJ, Hammer HB, Mathiessen A, Kvien TK, Semb AG. The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: A 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tocilizumab. PLoS One 2015;10:e0130709. doi:10.1371/journal.pone.0130709. PMID: 26114946.
   PubMed Web of Science ®Google Scholar